Prime Highlights-
- Yazen secured funding led by Verdane, with Evli Growth Partners joining, to scale its medical obesity care model across Europe.
- Seventy percent of Yazen patients stay in treatment after 12 months, against 20 to 50 percent stopping within a year internationally.
Key Facts-
- Yazen operates in eight European countries and has over 50,000 patients in active treatment today.
- The company employs 290 people, including 210 clinical staff and 115 licensed doctors across its teams.
Background-
Swedish digital healthcare provider Yazen has raised new funding in a round led by European growth investor Verdane. Previous lead investor Evli Growth Partners (EGP) also took part.
Yazen will use the capital to scale its evidence-based obesity care model across Europe. The company treats obesity as a chronic disease and pairs weight-loss medication with ongoing digital care from a multidisciplinary team.
Based in Sweden, Yazen operates in eight countries, including Norway, Denmark, the Netherlands, the United Kingdom, Germany, Switzerland and Spain. More than 50,000 patients are in treatment on the platform now, and over 70,000 have received help in total. The company employs 290 people, including 210 clinical staff and 115 licensed doctors.
Yazen points to its own 2025 study, which found that 70 percent of patients stay in treatment after 12 months. International data shows that 20 to 50 percent of patients stop within a year.
CEO Fredrik Meurling said the deal gives the company a strong long-term financial base. He said Yazen can now build a European healthcare platform that reaches hundreds of thousands of patients and eases pressure on public health systems.
Verdane picked Yazen after reviewing the European market, citing its clinical outcomes, medical quality and patient focus. Principal Cecilia Nytorp called the company a reliable and scalable leader in medical weight management. Chairman Mikael Hed said the funds will help Yazen enter more markets and widen treatment into cardiometabolic care.
